- Durham, NC-based Bioventus (BIOV) is set for its IPO of 8,823,529 shares of Class A common stock at $16 - 18.
- The medical technology firm develops orthobiologic products for patients with a broad range of musculoskeletal conditions. According to the company, its clinically effective and cost efficient products provide minimally invasive solutions that enhance the body's natural healing processes.
- The company has four business segments: Active Healing Therapies - U.S. and International, led by the Exogen system for long bone stimulation for fracture healing and hyaluronic acid, a viscosupplementation therapy for osteoarthritis pain relief; Surgical, a portfolio of bone graft substitutes, including the OsteoAMP allogeneic growth factor; BMP, its proprietary bone morphogenetic protein bone graft.
- 2015 Financials ($M): Revenues: 253.7 (+4.4%); Operating Expenses: 163.2 (+4.3%); Net Loss: (38.1) (-129.3%); CF Ops: 18.9 (+25.2%).